ReviewExpert opinion on biological therapy2012
Poxviral vectors for cancer immunotherapy.
Review in Expert opinion on biological therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-Nutrients · 2020Article
- Review
- Treatment of Metastatic Disease through Natural Killer Cell Modulation by Infected Cell Vaccines.Viruses · 2019Review
- Voluntary Wheel Running Does Not Alter Mortality to or Immunogenicity of Vaccinia Virus in Mice: A Pilot Study.Frontiers in physiology · 2017Article
- A Perspective of Immunotherapy for Prostate Cancer.Cancers · 2016Review
- Vaxvec: The first web-based recombinant vaccine vector database and its data analysis.Vaccine · 2015Article
- Six host-range restricted poxviruses from three genera induce distinct gene expression profiles in an in vivo mouse model.BMC genomics · 2015Article
- Emerging immunotherapies for bladder cancer.Current opinion in oncology · 2015Review
- Trial watch: Naked and vectored DNA-based anticancer vaccines.Oncoimmunology · 2015Article
- Identification of nucleotide-level changes impacting gene content and genome evolution in orthopoxviruses.Journal of virology · 2014Article
- Gene therapy in pancreatic cancer.World journal of gastroenterology · 2014Review
- Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara.Journal of virology · 2014Article
- Development and comparison of a quantitative TaqMan-MGB real-time PCR assay to three other methods of quantifying vaccinia virions.Journal of virological methods · 2014Article
- Enhancing poxvirus vectors vaccine immunogenicity.Human vaccines & immunotherapeutics · 2014Review
- Dramatic and prolonged PSA response after retreatment with a PSA vaccine.Clinical genitourinary cancer · 2013Article
- Viral vectors for vaccine applications.Clinical and experimental vaccine research · 2013Article
- Article
- Primer on tumor immunology and cancer immunotherapy.Journal for immunotherapy of cancer · 2013Review
- A replication-incompetent CD154/40L recombinant vaccinia virus induces direct and macrophage-mediated antitumor effectsOncoimmunologyArticle
- Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Il Giornale di chirurgiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionPoxviral vaccines have been given to over 1 billion people in the successful global eradication of smallpox. Recombinant poxviruses have been investigated extensively as a novel immunotherapy for cancer, undergoing several iterations to optimize their immunogenicity and efficacy. The current platform expressing multiple costimulatory molecules plus a tumor-associated antigen such as PSA, that is, PSA-TRICOM (PROSTVAC-V/F), is promising and is currently in a Phase III randomized, placebo-controlled clinical trial in metastatic castration-resistant prostate cancer. AREAS COVERED: This review discusses the clinical development of poxviral-based cancer vaccines, with a particular focus on the rationale for combining vaccines with other treatment modalities, including radiotherapy, chemotherapy, hormonal therapy, other immune-based therapies and molecularly targeted therapy. We also discuss the importance of appropriate patient selection in clinical trial design. EXPERT OPINION: Preclinical and early clinical studies employing poxviral-vector vaccines have shown promising results with this novel immunologic approach, both alone and combined with other therapies. The challenges of translating the science of immunotherapy to clinical practice include clinical trial design that includes appropriate patient selection, appropriate end points and identification of meaningful surrogate biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.